Freehold, NJ, May 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MEDIFIRST SOLUTIONS, INC. (MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device and a provider of Specialty Pharmacy Drug Consulting Services and Distributor of USA Pharma CBD, is pleased to provide a laser sales update.
Medifirst Solutions is pleased to announce that a high school in Nebraska has successfully completed a test trial using the Time Machine Therapeutic Laser for sports related injuries. After extensive usage, the trial resulted in very positive results with injuries ranging from minor or serious. Working in conjunction with a Physical Therapist at the school, the medical professionals on site specifically saw substantial improvement with students with various Achilles injuries including post-surgical recovery. Satisfied with the positive results, the school purchased its first laser for sport related injuries. Commented Medifirst President Bruce J. Schoengood, “Using the laser for sports injuries and having a school purchase a unit, both opens a new market as well as continues to validate the positive results we see every day with our laser. Sports injuries are most often associated with immediate pain and swelling and we believe our laser can be a very effective tool for medical professionals treating such injuries.”
Medifirst Solutions is also pleased to announce that after an extensive and successful trial, a Florida based Obstetrician-gynecologist (OB-GYN) has purchased the Time Machine Infrared Laser. The trial feedback indicated positive results for reduced scarring after C-sections as well as positive results as related to intravaginal tissues associated with inflammation and cysts. Continued Mr. Schoengood, “We are very excited to receive positive feedback from physicians including a purchase of our laser. There are over one million C-sections every year in the US and this represents a potential whole new market for the Time Machine Laser.”
Dr. Ronald L. Rubin, Medical Director for Medifirst, commented, “I believe the Time Machine Laser is an important tool for physicians and healthcare professionals in the battle to decrease and eliminate pain in the great majority of injuries whether at home, work, car or on the playing field. I am thrilled to see my colleagues see first-hand the great results I have seen for the last several years. We will continue to work with doctors of all specialties to expand the use and cope of our therapeutic laser.”
About the Time Machine Laser
The Time Machine Laser is the only all-in-one, affordable, FDA cleared, Infrared, 810nm, 2000mW power, small, hand-held portable laser marketed for pain relief in the U.S. The Time Machine Laser, which has been extensively tested and approved by Intertek for safety and electrical standards, has the power and frequency often found in large and expensive stationary units and at a fraction of the cost. Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Laser is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.
The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Contact: Investor Relations
Phone: (732) 786-8044